Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit
October 12 2021 - 4:01PM
Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that
Mark McKenna, Chairman and Chief Executive Officer and Allison Luo,
M.D., Chief Medical Officer, will participate in a fireside chat at
the Jefferies Virtual Next Generation IBD Therapeutics Summit on
Tuesday, October 19, 2021 at 11:30 a.m. ET.
A live and archived webcast of the fireside chat
will be available via the Events & Webcasts section of the
Prometheus Biosciences website. A replay of the presentation will
be available for 30 days following the event.
About Prometheus Biosciences
Prometheus Biosciences, Inc. is a clinical-stage biotechnology
company pioneering a precision medicine approach for the discovery,
development, and commercialization of novel therapeutic and
companion diagnostic products for the treatment of immune-mediated
diseases, starting first with inflammatory bowel disease (IBD). The
Company’s precision medicine platform, Prometheus360, combines
proprietary machine learning-based analytical approaches with one
of the world’s largest gastrointestinal bioinformatics databases to
identify novel therapeutic targets and develop therapeutic
candidates to engage those targets.
The Company’s lead candidate, PRA023, is an IgG1 humanized
monoclonal antibody (mAb) for the treatment of the two most common
forms of IBD, Ulcerative Colitis (UC) and Crohn’s Disease
(CD). The Company has initiated enrollment in a Phase 2 trial
in UC patients and a Phase 2a trial in CD patients, each utilizing
a genetic-based companion diagnostic designed to identify patients
more likely to respond to PRA023.
Prometheus Biosciences Contact:Noel KurdiVP
Investor Relations and Communications(646)
241-4400nkurdi@prometheusbiosciences.com
Media Contact:Jake RobisonCanaleComm, an
Ashfield Health Company(619)
849-5383jake.robison@canalecomm.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Sep 2023 to Sep 2024